{"id":864,"date":"2020-08-26T09:32:18","date_gmt":"2020-08-26T09:32:18","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/examining-links-between-breast-cancer-second-primary-cancer-and-inherited-genetic-mutations\/"},"modified":"2021-01-08T11:08:41","modified_gmt":"2021-01-08T11:08:41","slug":"examining-links-between-breast-cancer-second-primary-cancer-and-inherited-genetic-mutations","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/examining-links-between-breast-cancer-second-primary-cancer-and-inherited-genetic-mutations\/","title":{"rendered":"Examining links between breast cancer, second primary cancer and inherited genetic mutations"},"content":{"rendered":"<p><span lang=\"EN-GB\">Rates of inherited mutations in genes other than BRCA1\/2 are twice as high in breast cancer patients who have had a second primary cancer \u2013 including, in some cases, different types of breast cancer \u2013 compared to patients who have only had a single breast cancer. But the rates of these mutations were still found to be low overall, meaning it\u2019s difficult to assess whether and how these individual mutations may drive the development of cancer. The study from the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania also investigated the use of polygenic risk scores \u2013 which have recently been added to some commercial clinical multiplex genetic testing panels. Kara N. Maxwell, MD, PhD, an instructor of Hematology-Oncology and the study\u2019s lead author, presented the findings at the 2018 American Society of Clinical Oncology Annual. <\/span><br \/>\n<span lang=\"EN-GB\">Genetic testing can help identify patients have a genetic predisposition that puts them at risk for developing cancer. Recently, new therapies called PARP inhibitors have been FDA approved to specifically target cancers caused by certain mutations \u2013 such as BRCA1\/2, which carry a lifetime breast cancer risk of as much as 85 percent and 50 percent for ovarian cancer, as well as higher risks of pancreatic, prostate and other cancers.<\/span><br \/>\n<span lang=\"EN-GB\">\u201cWe need to gain a better understanding of why patients who have multiple cancers may be susceptible to them, and that work needs to go beyond the common genes we\u2019re already been looking at,\u201d Maxwell said.<\/span><br \/>\n<span lang=\"EN-GB\">The team \u2013 led by Susan M. Domchek, MD, executive director of the Basser Center for BRCA, and Katherine L. Nathanson, MD, deputy director of the Abramson Cancer Center, specifically looked at patients who did not have a BRCA1\/2 mutation and tested them for a panel of 15 different genetic mutations. They evaluated 891 patients who had a second primary cancer \u2013 breast or otherwise \u2013 after initial breast cancer and compared them to 1,928 who only had a single breast cancer. About eight percent of patients who had second primary cancers had mutations, compared to just four percent of patients from the single cancer cohort. The current threshold for whether or not genetic testing is recommended is five percent.<\/span><br \/>\n<span lang=\"EN-GB\">\u201cOur data show that patients who have had multiple primary cancers should undergo genetic testing, and likely this holds true for a number of other types of second cancer,\u201d Maxwell said. \u201cHowever, the overall numbers are still low, which shows the level of uncertainty that still exists and highlights the need for further research.\u201d<\/span><br \/>\n<span lang=\"EN-GB\">The research also evaluated polygenic risk scores, a somewhat controversial metric recently added to some commercial clinical multiplex genetic testing panels. Polygenic risk scores are determined by how many single nucleotide polymorphisms (SNPs) a person has. SNPs are common variants with smaller effect sizes, and if a patient has multiple of certain SNPs, they may be at a similar increased for cancer a as patients with a single rare mutation.<\/span><br \/>\n<span lang=\"EN-GB\">\u201cOur study does not provide strong evidence of higher polygenic risk scores in patients with more than one breast cancer,\u201d but many more patients will need to be studied to confirm this,\u201d Maxwell said.<\/span><\/p>\n<p><span lang=\"EN-GB\">Penn Medicine<link https:\/\/www.pennmedicine.org\/news\/news-releases\/2018\/june\/beyond-brca-examining-links-between-breast-cancer-second-primary-cancer-inherited-genetic-mutations _blank external-link-new-window \"Opens external link in new window\">www.pennmedicine.org\/news\/news-releases\/2018\/june\/beyond-brca-examining-links-between-breast-cancer-second-primary-cancer-inherited-genetic-mutations<\/link><\/span><br \/>\n<span lang=\"EN-GB\">&nbsp;<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rates of inherited mutations in genes other than BRCA1\/2 are twice as high in breast cancer patients who have had a second primary cancer \u2013 including, in some cases, different types of breast cancer \u2013 compared to patients who have only had a single breast cancer. But the rates of these mutations were still found [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-864","post","type-post","status-publish","format-standard","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=864"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/864\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}